- Home
- BTX vs CSTL Comparison
BTX vs CSTL Comparison
Compare BTX & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTX | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.3M | 806.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BTX | CSTL |
|---|---|---|
| Price | $7.46 | $24.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $47.17 |
| AVG Volume (30 Days) | ★ 695.4K | 261.5K |
| Earning Date | 11-01-2025 | 05-04-2026 |
| Dividend Yield | ★ 10.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $5.63 | $14.59 |
| 52 Week High | $7.50 | $44.28 |
Technical Indicators
Market Signals| Indicator | BTX | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 70.15 | 42.00 |
| Support Level | $6.88 | $21.77 |
| Resistance Level | $7.49 | $26.19 |
| Average True Range (ATR) | 0.17 | 1.17 |
| MACD | 0.09 | 0.22 |
| Stochastic Oscillator | 98.77 | 55.32 |
Price Performance
Historical ComparisonAbout BTX BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.